Common Chromosomal Syndromes in the Second Trimester





Professor of Obstetrics, Gynecology and Reproductive Biology, part time Massachusetts General Hospital, Harvard Medical School **Diagnostic Ultrasound Associates**



Disclosures


Bryann Bromley MD Relevant Financial Relationships: None




Bromley


Learning Objectives

- 1. Recognize the utility of the 2nd trimester sonogram as a screening tool for aneuploidy.
- 2. Describe the sonographic features of common aneuploidies.
- 3. Analyze and interpret markers for aneuploidy in the context of a priori risk.
- 4. Understand the significance of markers after cell-free DNA screening.
- 5. Assess the risk of pregnancy loss associated with invasive diagnostic testing.



Bromley





Bromley

Bromley

1

Lecture Outline

- 1. Components of Genetic Sonography
- 2. Genetic Sonography for detection of T 21
 - Structural Malformations
 - Markers for Trisomy 21
 - Bayes Theorem to calculate revised risk
 - GS after first trimester risk assessment
 - Markers in the era of cell-free DNA

3. Trisomy 18

- Structural Malformations
- Markers for Trisomy 18
- 4. Trisomy 13
- 5. Triploidy and Monosomy X

Bromley

Detailed Obstetrical Ultrasound Genetic Sonography

Independent of MA & Serum Screening

- 16 20 weeks gestation
- Biometry (BPD, FL, HL, NB)
- Structural Anomalies
- Search for "markers"




Bromley





Sonographic features that are often normal and transient.



Higher prevalence in the aneuploid population but most fetuses seen with a marker are euploid.

Bromley

Trisomy 21



Bromley

 Most common aneuploidy to result in a live birth.

- 1:504 second tri
- Sonographically elusive in the second trimester


Egan et al. OG 2000


Anomalies T 21: 20-30% by
prenatal USCongenital Heart DefectsGastrointestinal• Atrioventricular Canal
• Tetralogy of Fallot
• Atrial Septal Defects
• Ventricular Septal
Defects• Duodenal atresia
• Esophageal atresia
• Tracheoesophageal
Fistula
• Hirschsprung


Musculoskeletal, Genitourinary Tract, Ventriculomegaly *

Bromley


Stoll et al. Eur J Med Gen 2015







Dr. Langdon Down



" The face is flat and broad, destitute of prominence.....skin is deficient in elasticity, giving the appearance of being too large for the body....the nose is small.

London Hospital Reports 1866

Commonly Used 'Markers' for T21

- Nuchal Skin Fold Thickness (NF)
- Short Femur / Humerus
- Urinary Tract Dilation (UTD)
- Hyperechoic Bowel (HEB)
- Echogenic Intracardiac Focus (EIF)
- Nasal Bone (NB)

Bromley





Courtesy of Dr. Nyberg

Nuchal Fold: 40-50% of T21 Axial Scan: thalami, cerebellum Measure: occipital Overangling 1 D 0.61cr

Bromley


Bromley

- cerebral peduncles,
- bone to skin edge
- spuriously large measurement


Benacerraf et al. NEJM 1987


Nuchal Fold: Increases With Gestational Age ≥ 6 mm abnormal ■ ≥ 5 mm 'borderline' MoM


Bromley



* Def. of hypoplastic NB not uniform among studies (< 2.5 mm , < .75 MoM, < 5%, BPD/NBL < 10)









Echogenic Intracardiac Focus


- Discrete "dot" in the cardiac ventricle which is as bright as bone
- Most commonly in LV
- Pathologically represents a calcified papillary muscle

Bromley

Roberts DJ et al. Human Pathology 1992








LR: C	LR: Clusters of Markers			
# Markers	Nyberg 2001	Bromley 2002	FaSTER 2009	
0	0.4	0.2	0.46	
1	2	1.9	3.1	
2	10	6.2	21	
≥ 3	115	80	170	
nley				


LR of Isolated Markers			
I. Marker	Nyberg 2001	Smith-B. 2001	Bromley 2002
NF	11	17	NC
Humerus	5.2	7.5	5.8
НВ	6.7	6.1	NC
Femur	1.5	2.7	1.2
UTD	1.5	1.9	1.5
Bromley	1.8	2.8	1.4






Statistically More Robust		
	R	
A Priori Risk x	+/-LR Each Marker	Revised Risk

	LR from Meta-Analysis					
	Marker	LR+	CI	LR-	CI	
	NF	23.3	14.35-37.83	0.80	0.74-0.85	
	NB (a/h)	23.27	14.23-38.06	0.46	0.36-0.58	
	EIF	5.83	5.02-6.77	0.80	0.75-0.86	
	HEB	11.44	9.05-14.47	0.90	0.86-0.94	
	Short F	3.72	2.79-4.97	0.80	0.73-0.88	
	Short H	4.81	3.49-6.62	0.74	0.63-0.88	
	UTD	7.63	6.11-9.51	0.92	0.89-0.96	
Bro	Agathokleous et al. UOG 2013 Bromley					




DR (%) T	DR (%) T21: 5% FP			
Test	STD	pUS		
GS alone	69	**		
Quadruple	81	90		
Combined	81	90		
Integrated	93	98		
Stepwise	97	98		
Contingent	95	97		
Aagaard-T ley	Aagaard-Tillery et al: OG 2009			



Cell free DNA- ≥ 10 wks GA			
A Contraction of the second se	Abnl	Sens.	FPR
	T21	99.2%	.09%
	T18	96.3%	.13%
	T13 91.0% .13% 45X 90.3% .23% SCA 93.0% .14%	.13%	
		.23%	
		.14%	
	X,Y	96.6%	1.1%
W	(Gil et al. UOG	2015,
Bromley			

	ee DNA: The in sitive" or "Neg	nplication of a ative" Result	
	High Risk > 99% (+LR)	Low Risk < 1:10,000 (-LR)	
T21	1240	100	
T18	650	31	
T13	460	13	
Chance	of being affecte a priori		
		PerinatalQuality.or	
omley	Grata	acós and Gil Fetal Diagn Ther :	



Fetal imaging: Executive Summary of a Joint Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, American Institute of Ultrasound in Medicine, American College of Obstetricians and Gynecologists, American College of Radiology, Society for Pediatric Radiology, and Society of Radiologists in Ultrasound Fetal Imaging Workshop http://dx.doi.org/10.1016/j.ajog.2014.02.028



"In women who have undergonecell free DNA testing.... the association of isolated soft markers and aneuploidy is generally no Bromley longer relevant."






NF • A/H NB • HEB • UTD • Short Femur


Possible association with other genetic abnormalities (aneuploidies, gene deletions, CF) or adverse outcome (infection, growth restriction, bowel abnormalities and UTD.

Mild Ventriculomegaly

Bromley

Bromley







- Small CBL
- **Posterior Fossa**
- **Neural Tube Defect**
- Agenesis Corpus Callosum




Bromley







Bromley


1 D 1.19cm





































Bromley

CNS

NTD Microcephaly

Cleft

Bromley

Midline Facial

 Hypotelorism Proboscis

Trisomy 13: Patau Syndrome

1:6000 births

- > 90% detected by US in 2nd tri
- 50% IUFD
- Median Survival 12 days; 20% 1 year; 13% 10 years

Bromley



Barry et al. A J Med Gen Part A 2015 Nelson et al. JAMA 2016

Trisomy 13: Patau Syndrome **Structural Anomalies** Holoprosencephaly Posterior Fossa

Trisomy 13: Patau Syndrome


Structural Anomalies

- Cardiac Defects (80%)
- Oomphalocele
- CDH
- Renal Abnormalities
- Abnormal extremities
 - Postaxial Polydactyly
 - Club Feet


































Triploidy


Structural Anomalies (92%)

- CNS
 - Posterior Fossa
 - Ventriculomegaly (37%)
 - NTD
- Cardiac Defects (34%)
- Facial Defects
 - Hypertelorism
 - Micrognathia (26%)
- Abnormal Extremities
 Syndactyly (52%)

Bromley











Bromley


Placental Pathology (28.6%)


- Placental hydropic changes associated with extra haploid set of paternal origin
- Placentas are small with extra maternal haploid set






















Cardiac Defects (13%)

- Left sided defects
- Coarctation Aorta
- Aortic Valve Anomalies



Bromley





Conclusions

- Each chromosomal aneuploidy has a relatively distinct constellation of findings in the 2nd tri
- GS detects 70% of fetuses with Trisomy 21 and 90⁺ % when including other screening methods
- Markers can be used to adjust the *a priori* risk of aneuploidy in the 2nd tri, including patients with 1st tri screening combined screening

Bromley

Conclusions

- GS detects 90% 100% of those with Trisomy 18 and 13
- Isolated markers are not likely of clinical relevance with respect to aneuploidy after negative cell-free DNA screening –but carry a residual risk of other outcomes
- The procedure related risk of diagnostic testing is low

Bromley

Key References

Aagard-Tillery KM, Malone FD, Nyberg DA et al. Role of Second-Trimester Genetic Sonography after Down SyndromeScreening. Obstet Gynecol 2009: 114:1189-1196.

Agathokleous M, Chaveeva P, Poon LCY, et al. Meta analysis for second trimester markers for trisomy 21. Ultrasound Obstet Gynecol 2013; 41: 247-261.

Akolekar R, Beta J, Picciarelli G, Ogilvie C, D'Antonio F. Procedure-related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2015;45:16-26.

Benacerraf B. Ultrasound of Fetal Syndromes. 2nd Edition. Elsevier. 2008

Bromley B, Lieberman E, Shipp TD, et al. The Genetic Sonogram: A method of risk assessment for Down syndrome in the second trimester. J Ultrasound Med 2002; 21: 1087-1096

Key References

Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol. 2015;45:249-66

Reddy UM, Abuhamad AZ, Levine D, et al. Fetal Imaging Executive Summary. Obstetrics and Gynecology. 2014

Wax J, Minkoff H, Johnson A, Coleman B, Levine D, Helfgott A, et al. Consensus report on the detailed fetal anatomic ultrasound examination: indications, components, and qualifications. J Ultrasound Med. 2014;33:189-95.

OG: Obstet Gynecol UOG: Ultrasound Obstet Gynecol PD: Prenat Diagn JUM: J Ultra Med